GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » Institutional Ownership

ELEV (Elevation Oncology) Institutional Ownership : 67.62% (As of Apr. 25, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Elevation Oncology's institutional ownership is 67.62%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Elevation Oncology's Insider Ownership is 1.10%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Elevation Oncology's Float Percentage Of Total Shares Outstanding is 94.67%.

Elevation Oncology Institutional Ownership Historical Data

The historical data trend for Elevation Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevation Oncology Institutional Ownership Chart

Elevation Oncology Historical Data

The historical data trend for Elevation Oncology can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 11.60 14.32 16.06 15.19 15.18 15.41 15.47 15.50 15.33 15.48

Elevation Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Elevation Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » Institutional Ownership
Comparable Companies
CLRB SLGL NRXS MEIP COCP PRTG SYBX ZEOX CING INAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
101 Federal Street, Suite 1900, New York, NY, USA, 02110
Website
https://www.elevationoncology.com
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Executives
Tammy Furlong officer: CHIEF FINANCIAL OFFICER C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen officer: Chief Medical Officer C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff other: Managing Member PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms director, other: Managing Member 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin director C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106